Global Neurodegenerative Disorder Therapeutics Market - Improvement in the healthcare infrastructure is likely to create new opportunity for the market
August 13, 2020 10:34 ET
|
PMI
Covina, CA, Aug. 13, 2020 (GLOBE NEWSWIRE) -- The report "Global Neurodegenerative Disorder Therapeutics Market, By Indication Type (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis,...
The New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS
July 08, 2020 17:01 ET
|
Biogen Inc.
Tofersen is an investigational molecule for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), the second most common genetic form of ALS, a progressive neurodegenerative diseaseFinal...
Biogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020
June 04, 2020 07:30 ET
|
Biogen Inc.
Full analysis of the CLE part of the LILAC study reinforces positive top-line results; participants who received BIIB059 (anti-BDCA2) demonstrated statistically significant reduction of disease...
Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy
December 13, 2019 07:30 ET
|
Biogen Inc.
CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Today, Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 2 PASSPORT study of gosuranemab (BIIB092) for progressive supranuclear...
Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE)
December 03, 2019 07:30 ET
|
Biogen Inc.
The Phase 2 LILAC study met its primary endpoints, demonstrating statistically significant reduction of disease activity in patients with CLE and SLE who received BIIB059 compared to placeboPositive...
UPMC Health Plan and Biogen Announce Groundbreaking Value-Based Agreement for Multiple Sclerosis Treatments
November 14, 2019 10:43 ET
|
UPMC Health Plan
Pittsburgh, Nov. 14, 2019 (GLOBE NEWSWIRE) -- UPMC Health Plan announced today that it has entered into a value-based agreement with Biogen for Tecfidera® (dimethyl fumarate) and Avonex® (interferon...
Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019
November 04, 2019 16:30 ET
|
Biogen Inc.
CAMBRIDGE, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced it will host live webcasts of its oral presentation and a Q&A session related to its Alzheimer’s disease...
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
October 22, 2019 06:30 ET
|
Biogen Inc.
New analysis of larger dataset showed that aducanumab reduced clinical decline in patients with early Alzheimer’s disease as measured by the pre-specified primary and secondary endpoints Based on...
Biogen Announces Leadership Update
October 01, 2019 08:00 ET
|
Biogen Inc.
Dr. Alfred Sandrock is named Executive Vice President, Research and Development and continues as Chief Medical Officer Dr. Alphonse Galdes appointed Executive Vice President, Pharmaceutical...
Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index
September 17, 2019 07:30 ET
|
Biogen Inc.
CAMBRIDGE, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it has been ranked the #1 biotechnology company on the Dow Jones Sustainability World Index (DJSI...